For personal use only

Transcription

1 Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group Level 8, 1 Martin Place, Sydney SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd

2 Sirtex is a Commercial Stage Oncology Company Formed in 1997 to commercialise SIR-Spheres microspheres Listed on the ASX on 24 th August 2000 Relocated from Perth to Sydney December 2000 Established USA S&M office 2002 Established EU S&M office 2003 Established US manufacturing facility February 2008 Established Singapore regional office and manufacturing facility September SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd

3 Sirtex Medical: An Australian Company ASX SRX Market cap (8 Oct 12): ~$548 million Shares on issue: 55.8 million 30 June 12: $49 million No. Of Shareholders: ~ 3200 Top-20 holders: 85% Major holders: A$ Hunter Hall 27% ACN % Perpetual 7% Platypus 7% Share price 30 th June each year Year 2

4 Sirtex has achieved 33 consecutive quarters of growth Profitable and pays dividends Healthy cash flow Expanding markets Increased investment in marketing, clinical and R&D Improved business process and systems No debt 3

5 Sirtex Out-Performed the ASX 200 Healthcare Index 4

6 SIR-Spheres microspheres are a proven and highly effective treatment for liver cancer Selective Internal Radiation Therapy (SIRT) targets tumours in the liver while maintaining a low radiation dose to normal tissue 5

7 Sirtex has achieved a 5 year Compound Annual Growth Rate of 23.8% Sales revenues $ thousands Dose sales Number of units APAC EMEA USA 38,125 65,559 64,333 70,290 82,627 2,581 3,658 4,171 4,977 6,141 For personal use only FY08 FY09 FY10 FY11 FY12 FY08 FY09 FY10 FY11 FY12 6

8 2012 Key Financials reflect a sound business Dose sales ,977 6,141 Number sold 23% Product revenue $ thousands 18% Profit before tax $ thousands 54% Net profit after tax $ thousands 49% Operating cash flow $ thousands 31% Dividends declared (Fully Franked) 70,290 82,627 14,354 11,483 15,286 3,904 22,118 17,103 19,987 5,557 $ thousands 42% 7

9 Profit After Tax and Operating Profit* Profit after tax $ thousands Operating Profit* $ thousands * Operating Profit is defined as EBIT excluding the impact of Foreign Exchange and Abnormals (UWA proceedings). 8

10 Treating Liver Cancer 9

11 In general terms, the main categories of treatment available for human cancers include 1. Surgery 2. Chemotherapy 3. Radiotherapy 4. Biologic therapies (in more recent times) remove it poison it irradiate it interrupt it 10

12 But unfortunately for liver cancer, not all of these treatments have been widely available Surgery Chemotherapy Radiotherapy Because... Normal liver tissue is sensitive to radiation Organs near the liver are sensitive to radiation Therefore... Liver cancer patients have missed out on a highly effective cancer treatment option 11

13 When liver cancers grow, they develop their own blood supply 12

14 SIR-Spheres microspheres are placed into the blood supply to the liver cancers 13

15 And deliver radiation therapy directly to the liver cancer, while minimizing damage to the normal tissue 14

16 15

17 SIR-Spheres microspheres are currently used to treat <1% of the eligible patient population Colorectal Cancer Hepatocellular Carcinoma Global annual incidence (1) 1,235, ,000 Disease universe Annual incidence in Sirtex s markets (2) 965, ,000 Disease population in Sirtex s markets Patients eligible for SIR- Spheres microspheres (3) 279, ,000 Contestable population in Sirtex s markets Current market penetration < 1% <1% Market penetration 16 (1) International Agency for Research on Cancer, World Health Organization, GLOBOCAN 2008, Cancer Incidence, Mortality and Prevalence Worldwide in (2) Sirtex markets = APAC: Australia, China, Hong Kong, India, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand. EMEA: Austria, Belgium, Egypt, Estonia, Finland, France, Germany, Greece, Israel, Italy, Poland, Portugal, South Africa, Spain, Sweden, Switzerland, The Netherlands, Turkey, United Kingdom. Americas: Argentina, Brazil, Canada, Mexico, USA. (3) Sirtex data & analysis. See Appendix 1: Contestable Market Analysis.

18 Level 1 evidence should elevate SIRT from a salvage therapy to an earlier line of treatment With Level 1 data: SIRT elevated to 1 st -line or post 1 st -line therapy 279,000 patients eligible for SIRT 100 patients with inoperable mcrc 85% 85 receive 1 st -line chemo (1) 75% 64 receive 2 nd -line chemo 25% 75% 25% 15% Receive no further palliative treatment 16 receive 3 rd -line chemo Unknown Unknown 2012: SIRT confined to last-line salvage therapy Salvage therapies e.g. SIRT Small number of patients eligible for SIRT, due to attrition 17 (1) NICE Technology Appraisal TA 93: Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Aug ScHARR. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. January 2005.

19 Sirtex s $60 million investment in clinical studies over 5 years should deliver necessary Level 1 clinical evidence Study name (1) Start Size % Patient recruitment (2) Type of liver cancer SIRFLOX % mcrc (3) FOXFIRE FOXFIRE Global % mcrc SORAMIC % HCC (4) SIRveNIB % HCC SARAH % HCC Total 2, (1) Each study is a randomised controlled trial (RCT) (2) Percent completion of patient recruitment as at end August (3) mcrc = metastatic colorectal cancer. (4) HCC = hepatocellular carcinoma.

20 Clinical studies recruitment is accelerating with initial Level 1 data due in late 2014 Global clinical study recruitment Patient numbers $12.2 million investment in FY2012 ( 18%) resulted in recruitment for FY2012 ( 61%) globally SIRFLOX study due to complete recruitment early 2013 SIRFLOX study data due late 2014 SIRveNIB study due to complete recruitment

21 20

22 2020 Vision is our guide to manage growth Structuring for long term sustainable business expansion Production capacity Hospitals Training Sales & Marketing Clinical & Medical Support structures SIR-Spheres evolution 21

23 Sirtex invested $6.6 million in R&D during 2012 SIR-Spheres Evolution Program New delivery system will simplify and improve method of administering Imageable microspheres will improve work-up and treatment monitoring Computer-based patient treatment planning system to tailor doses New Technology Focus is on unmet needs in Oncology Goal is maximise clinical outcomes and make core product scalable Work is based on customer needs and feedback from users in all markets 22

24 Summary and Outlook Continuing growth expected Primary focus on promoting and developing SIR-Spheres microspheres Longer term objective to provide a wider choice of targeted and tailored oncology treatment options for a wider range of patients Strong position to take advantage of future opportunities 2020Vision strategic plan will drive solid growth into the next decade 23

25 37% dose sales growth in first quarter FY2013 USA 1185 doses sold (up 42%) 1,786 Total Dose Sales EMEA (Europe Mid East & Africa) 433 doses sold (up 26%) APAC (Asia Pacific) 168 doses sold (up 33%) 24

26 25 Thank You